DDInter557 DDInter1458
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Dihydroergotamine {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) is bound by {v} (Compound) Phenylpropanolamine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Flushing
Flushing {u} (Side Effect) is caused by {v} (Compound) Phenylpropanolamine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Dihydroergotamine {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) interacts with {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Phenylpropanolamine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Flushing
Flushing {u} (Side Effect) is caused by {v} (Compound) Tranylcypromine
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenylpropanolamine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Amphetamine
Amphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylpropanolamine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Euphoric mood
Euphoric mood {u} (Side Effect) is caused by {v} (Compound) Phentermine
Phentermine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) is bound by {v} (Compound) Phenylpropanolamine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Dihydroergotamine {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) regulates {v} (Gene) RRP1B
RRP1B {u} (Gene) is downregulated by {v} (Compound) Phenylpropanolamine
Dihydroergotamine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Phenylpropanolamine (Compound)
Dihydroergotamine (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Phenylpropanolamine (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Dihydroergotamine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) interacts with ADRB1 (Gene) and ADRB1 (Gene) is bound by Phenylpropanolamine (Compound)
Dihydroergotamine (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Tranylcypromine (Compound) and Tranylcypromine (Compound) resembles Phenylpropanolamine (Compound)
Dihydroergotamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Amphetamine (Compound) and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Dihydroergotamine (Compound) causes Euphoric mood (Side Effect) and Euphoric mood (Side Effect) is caused by Phentermine (Compound) and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Phenylpropanolamine (Compound)
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Bromocriptine (Compound) and Bromocriptine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Dihydroergotamine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) regulates RRP1B (Gene) and RRP1B (Gene) is downregulated by Phenylpropanolamine (Compound)